TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,721.40 | 31.90 | -0.36% |
| CAC 40 | 7,953.77 | 14.16 | -0.18% |
| DAX 40 | 23,162.92 | 17.61 | -0.08% |
| Dow JONES (US) | 46,138.77 | 47.03 | 0.10% |
| FTSE 100 | 9,507.41 | 44.89 | -0.47% |
| HKSE | 25,830.65 | 99.38 | -0.38% |
| NASDAQ | 22,564.23 | 131.38 | 0.59% |
| Nikkei 225 | 48,537.70 | 165.28 | -0.34% |
| NZX 50 Index | 13,364.13 | 37.23 | 0.28% |
| S&P 500 | 6,642.16 | 24.84 | 0.38% |
| S&P/ASX 200 | 8,447.90 | 35.60 | -0.42% |
| SSE Composite Index | 3,946.74 | 6.93 | 0.18% |